Mavrilimumab for severe COVID-19 – Authors' reply

類似資料

• Effect of anakinra in COVID-19 – Authors' reply
  著者:: Cavalli, Giulio, 等
  出版事項: (2020)
• Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic
  著者:: Cavalli, Giulio, 等
  出版事項: (2020)
• Anakinra for patients with COVID-19 – Authors' reply
  著者:: Cavalli, Giulio, 等
  出版事項: (2020)
• Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation – Authors' reply
  著者:: Cavalli, Giulio, 等
  出版事項: (2021)
• GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study
  著者:: De Luca, Giacomo, 等
  出版事項: (2020)